Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
|
|
Comera Life Sciences Holdings, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
8-K
| Quarterly results |
| 05/19/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/12/2023 |
8-K
| Quarterly results|
Docs:
|
"Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights – Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera’s pipeline candidate CLS-001 , highlighted by identification of a lead formulation – – Expanded Comera’s patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 — Comera Life Sciences Holdings, Inc. , a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ended March 31, 2023, and provided a business update. “..." |
|
| 05/05/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/24/2023 |
8-K
| Investor presentation |
| 03/16/2023 |
8-K
| Quarterly results |
| 01/06/2023 |
8-K
| Investor presentation |
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"Form of Common Stock Warrant",
"Securities Purchase Agreement, by and among Comera Life Sciences Holdings, Inc. and the Purchasers defined therein",
"Registration Rights Agreement dated January 4, 2023, by and among Comera Life Sciences Holdings, Inc. and the Purchasers defined therein",
"Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules WOBURN, Mass.—January 4, 2023— Comera Life Sciences Holdings, Inc . , a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that it has completed a private placement to existing stockholders, of 2,406,242 units, at a purchase price of $1.48 per unit, with each unit consisting of one share of the Company's common stock and one five-year warrant to purchase two shares of the Company's common stock at an exercise price of $1.23 per share, pursuant to the terms of a Securities Purchase Agreement entered into on January 2, 2023. Gross proceeds from the private placement of approximately $3.6 mill..." |
|
| 11/23/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 09/02/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/31/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/29/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/25/2022 |
8-K
| Quarterly results |
|
|